Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350597 · ClinicalTrials.gov registry record · Phase 2
GM-CSF as Adjuvant Therapy of Melanoma
A Phase 2 study of Malignant Melanoma, sponsored by Northern California Melanoma Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00350597 is a Phase 2 study of Malignant Melanoma that has completed, run by Northern California Melanoma Center. The registered enrollment target is 50 participants, below the 181-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00350597, a Phase 2 study of Malignant Melanoma, has completed, sponsored by Northern California Melanoma Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to describe the immunological responses and clinical outcome associated with administration of recombinant human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) as surgical adjuvant therapy in patients with malignant melanoma who are at high risk for recurrence (Stage II T4, III and IV).
Conditions Studied
Interventions
- DRUG Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Study Locations (1)
California
- Northern California Melanoma Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2004-09 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00350597
The ClinicalTrials.gov registry entry for NCT00350597 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (72% lower). The listed sponsor is Northern California Melanoma Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is the first listed.
NCT00350597 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00350597 about?
NCT00350597 is a clinical study titled "GM-CSF as Adjuvant Therapy of Melanoma". This is a pilot study to describe the immunological responses and clinical outcome associated with administration of recombinant human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) as surgical adjuvant therapy in patients with malignant melanoma who are at high risk for recurrence (Stage...
What is the current status of trial NCT00350597?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2004-09. Estimated completion is 2010-07.
What conditions does trial NCT00350597 study?
This clinical trial studies the following conditions: Malignant Melanoma.
What interventions are being tested in trial NCT00350597?
The interventions under investigation include: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (DRUG).
Who is sponsoring clinical trial NCT00350597?
This trial is sponsored by Northern California Melanoma Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00350597 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
RECRUITING · Phase 2
-
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
COMPLETED · Phase 2
-
Phase II Trial of Allovectin-7® for Metastatic Melanoma
COMPLETED · Phase 2
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.